110 related articles for article (PubMed ID: 19440086)
1. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder.
Ghaemi SN; Gilmer WS; Dunn RT; Hanlon RE; Kemp DE; Bauer AD; Chriki L; Filkowski MM; Harvey PD
J Clin Psychopharmacol; 2009 Jun; 29(3):291-5. PubMed ID: 19440086
[TBL] [Abstract][Full Text] [Related]
2. Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study.
Iosifescu DV; Moore CM; Deckersbach T; Tilley CA; Ostacher MJ; Sachs GS; Nierenberg AA
CNS Neurosci Ther; 2009; 15(4):309-19. PubMed ID: 19889129
[TBL] [Abstract][Full Text] [Related]
3. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
4. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
Lindenmayer JP; Khan A
Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
[TBL] [Abstract][Full Text] [Related]
5. Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder.
Chengappa KN; Bowie CR; Schlicht PJ; Fleet D; Brar JS; Jindal R
J Clin Psychiatry; 2013 Nov; 74(11):1076-83. PubMed ID: 24330893
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial.
Miskowiak KW; Ehrenreich H; Christensen EM; Kessing LV; Vinberg M
J Clin Psychiatry; 2014 Dec; 75(12):1347-55. PubMed ID: 25099079
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder.
McIntyre RS; Soczynska JK; Woldeyohannes HO; Miranda A; Vaccarino A; Macqueen G; Lewis GF; Kennedy SH
Bipolar Disord; 2012 Nov; 14(7):697-706. PubMed ID: 23107220
[TBL] [Abstract][Full Text] [Related]
8. Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI.
Leijenaar JF; Groeneveld GJ; Klaassen ES; Leeuwis AE; Scheltens P; Weinstein HC; van Gerven JMA; Barkhof F; van der Flier WM; Prins ND
Alzheimers Res Ther; 2020 Jan; 12(1):10. PubMed ID: 31910895
[TBL] [Abstract][Full Text] [Related]
9. Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study.
Bruce J; Hancock L; Roberg B; Brown A; Henkelman E; Lynch S
Cogn Behav Neurol; 2012 Sep; 25(3):107-14. PubMed ID: 22960434
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled study of the impact of galantamine on anterograde memory impairment during electroconvulsive therapy.
Matthews JD; Siefert CJ; Blais MA; Park LT; Siefert CJ; Welch CA; Dubois CM; van Nieuwenhuizen AO; Rooney KO; Seabrook RC; Durham LE; Adams HC; Fava M
J ECT; 2013 Sep; 29(3):170-8. PubMed ID: 23519225
[TBL] [Abstract][Full Text] [Related]
11. Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine in healthy human subjects.
Hahn B; Shrieves ME; Olmstead CK; Yuille MB; Chiappelli JJ; Pereira EFR; Albuquerque EX; Fawcett WP
Psychopharmacology (Berl); 2020 Jan; 237(1):219-230. PubMed ID: 31686175
[TBL] [Abstract][Full Text] [Related]
12. Galantamine for vascular cognitive impairment.
Birks J; Craig D
Cochrane Database Syst Rev; 2006 Jan; (4):CD004746. PubMed ID: 23862185
[TBL] [Abstract][Full Text] [Related]
13. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.
Dyer MA; Freudenreich O; Culhane MA; Pachas GN; Deckersbach T; Murphy E; Goff DC; Evins AE
Schizophr Res; 2008 Jul; 102(1-3):88-95. PubMed ID: 18325740
[TBL] [Abstract][Full Text] [Related]
14. Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients.
Torrent C; Martinez-Arán A; Daban C; Amann B; Balanzá-Martínez V; del Mar Bonnín C; Cruz N; Franco C; Tabarés-Seisdedos R; Vieta E
Compr Psychiatry; 2011; 52(6):613-22. PubMed ID: 21295774
[TBL] [Abstract][Full Text] [Related]
15. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction.
Burdick KE; Braga RJ; Nnadi CU; Shaya Y; Stearns WH; Malhotra AK
J Clin Psychiatry; 2012 Jan; 73(1):103-12. PubMed ID: 22152405
[TBL] [Abstract][Full Text] [Related]
16. Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated, euthymic bipolar patients: a 6-year follow-up study.
Mora E; Portella MJ; Forcada I; Vieta E; Mur M
Psychol Med; 2013 Jun; 43(6):1187-96. PubMed ID: 22935452
[TBL] [Abstract][Full Text] [Related]
17. Galantamine for the treatment of cognitive impairments in people with schizophrenia.
Buchanan RW; Conley RR; Dickinson D; Ball MP; Feldman S; Gold JM; McMahon RP
Am J Psychiatry; 2008 Jan; 165(1):82-9. PubMed ID: 17986678
[TBL] [Abstract][Full Text] [Related]
18. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients.
Mur M; Portella MJ; Martínez-Arán A; Pifarré J; Vieta E
J Clin Psychiatry; 2008 May; 69(5):712-9. PubMed ID: 18435565
[TBL] [Abstract][Full Text] [Related]
19. Galantamine treatment of cognitive impairment in bipolar disorder: four cases.
Schrauwen E; Ghaemi SN
Bipolar Disord; 2006 Apr; 8(2):196-9. PubMed ID: 16542191
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and effects of galantamine on cognition in humans with cannabis use disorder.
Sugarman DE; De Aquino JP; Poling J; Sofuoglu M
Pharmacol Biochem Behav; 2019 Jun; 181():86-92. PubMed ID: 31082417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
